文献速递骨质疏松与钙磷/甲状旁腺

绝经后骨质疏松女性接受地舒单抗治疗长达10年的有创口腔操作与事件

Invasive Oral Procedures and Events in Postmenopausal Women With Osteoporosis Treated With Denosumab for Up to 10 Years.
PubMed 文献 · J Clin Endocrinol Metab · 2019-01-01

基于FREEDOM及其7年开放扩展研究,评估绝经后骨质疏松女性接受地舒单抗治疗期间有创口腔操作与事件(OPEs)及颌骨坏死(ONJ)情况。45.1%的应答者报告至少一次有创OPEs,扩展期ONJ暴露调整发生率为5.2/10000人年,报告OPEs者ONJ发生率0.68%高于未报告者0.05%,总体ONJ率低且完全随访病例均经治疗缓解。

要点

  • 地舒单抗治疗期间有创口腔操作常见,45.1%应答者报告至少一次。
  • 扩展期ONJ暴露调整发生率为5.2/10000人年,总体发生率低。
  • 报告有创口腔操作者ONJ发生率0.68%,高于未报告者的0.05%。

核心结论

  • 地舒单抗治疗绝经后骨质疏松女性中有创口腔操作常见且与ONJ发生率升高相关,但总体ONJ率低,完全随访病例均经治疗缓解。

研究设计与样本

  • 随机双盲安慰剂对照3年FREEDOM试验后接7年开放标签地舒单抗扩展研究,多中心多国临床试验。
  • 受试者为绝经后骨质疏松女性,随机接受皮下地舒单抗60 mg或安慰剂每6个月一次共3年,后开放标签地舒单抗7年。
  • 扩展第3年要求记录自扩展开始至第2.5年的有创OPEs史及前6个月口腔事件,此后每6个月问卷直至扩展结束。

主要发现

  • 45.1%的应答者报告至少一次有创OPEs(牙种植、拔牙、自然牙缺失、洁治/根面平整、颌骨手术)。
  • FREEDOM扩展期ONJ暴露调整发生率为5.2/10000人年。
  • 报告OPEs者ONJ发生率为0.68%,未报告者为0.05%。

临床怎么用

  • 地舒单抗治疗期间应关注有创口腔操作史,报告OPEs者ONJ风险相对较高但绝对风险低。
  • ONJ总体发生率低且完全随访病例均经治疗缓解,支持在必要时进行口腔操作并密切随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Antiresorptive therapy has been associated with osteonecrosis of the jaw (ONJ), an infrequent but potentially serious adverse event. OBJECTIVE: To assess information on invasive oral procedures and events (OPEs)-dental implants, tooth extraction, natural tooth loss, scaling/root planing, and jaw surgery-during the 7-year Fracture REduction Evaluation of Denosumab in Osteoporosis every 6 Months (FREEDOM) Extension study and to present details of positively adjudicated ONJ cases. DESIGN: Randomized, double-blind, placebo-controlled, 3-year trial (FREEDOM) followed by 7 years of open-label denosumab (FREEDOM Extension). At Extension Year 3, women were asked to record their history of invasive OPEs since the start of the Extension to Year 2.5 and oral events in the prior 6 months. The questionnaire was then administered every 6 months until the end of the Extension. SETTING: Multicenter, multinational clinical trial. PATIENTS: Postmenopausal women with osteoporosis. INTERVENTIONS: Subcutaneous denosumab 60 mg or placebo every 6 months for 3 years, then 7 years of open-label denosumab. MAIN OUTCOME MEASURES: Self-reports of OPEs and adjudicated cases of ONJ. RESULTS: Of respondents, 45.1% reported at least one invasive OPE. The exposure-adjusted ONJ rate in FREEDOM Extension was 5.2 per 10,000 person-years. ONJ incidence was higher in those reporting an OPE (0.68%) than not (0.05%). CONCLUSIONS: Although invasive OPEs were common in these denosumab-treated women and were associated with an increased ONJ incidence, the overall rate of ONJ was low, and all cases with complete follow-up resolved with treatment.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Watts NB, Grbic JT, Binkley N, et al. Invasive Oral Procedures and Events in Postmenopausal Women With Osteoporosis Treated With Denosumab for Up to 10 Years. J Clin Endocrinol Metab. 2019. PMID: 30759221. doi:10.1210/jc.2018-01965

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。